Patents Represented by Attorney, Agent or Law Firm Joseph A. Coppola
  • Patent number: 6528630
    Abstract: Isolated nucleic acid encoding calcium channel &agr;1F-subunits, including subunits encoded by nucleic acid that arises as splice variants of primary transcripts, is provided. Cells and vectors containing the nucleic acid and methods for identifying compounds that modulate the activity of calcium channels that contain &agr;1F-subunits are also provided.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: March 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Williams, Kenneth A. Stauderman, Michael M. Harpold
  • Patent number: 6387696
    Abstract: Isolated DNA encoding each of human calcium channel &agr;1-, &agr;2-, &bgr;- and &ggr;-subunits, including subunits that arise as splice variants of primary transcripts, is provided. Cells and vectors containing the DNA and methods for identifying compounds that modulate the activity of human calcium channels are also provided.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Michael M. Harpold, Steven B. Ellis, Mark E. Williams, Ann F. McCue
  • Patent number: 6362327
    Abstract: The invention discloses a cDNA consisting of human cyclooxygenase-2 cDNA attached to 3′ flanking sequence of human cyclooxygenase-1 methods for increasing the expression of human cyclooxygenase-2 in transformed cells and assays for preferentially and independently measuring cyclogenase-2 in samples.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: March 26, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Gary P. O'Neill, Joseph A. Mancini
  • Patent number: 6294559
    Abstract: This invention is directed to compounds and ligands that bind to peroxisome proliferator activated receptors (PPAR) &ggr;1 and &ggr;2 and which function as antiproliferative, antiviral and antitumour agents. The invention is also directed to the use of PPAR &ggr;1 and &ggr;2 to identify such compounds and methods of using the compounds for medical uses.
    Type: Grant
    Filed: August 3, 1998
    Date of Patent: September 25, 2001
    Assignee: Merck & Co., Inc.
    Inventor: Roy G. Smith
  • Patent number: 6290967
    Abstract: Vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability are disclosed. The vaccine formulations comprise an increased amount of a 6-carbon polyhydric alcohol (such as sorbitol), an increase amount of a disaccharide (such as sucrose) and an amount of a physiologically active buffer to adjust the pH from about 6.0 to about 7.0.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Su-Pi Sheu, Carl J. Burke
  • Patent number: 6224880
    Abstract: A method of immunizing against disease caused by Streptococcus pneumoniae is provided in which children are immunized at age 2 and again at age 4 months with a conjugated pneumococcal polysaccharide vaccine. These immunizations are followed by an immunization at 6 months with an unconjugated pneumococcal polysaccharide vaccine. Optionally, a fourth immunization at 12 months with unconjugated pneumococcal polysaccharide vaccine is given.
    Type: Grant
    Filed: September 2, 1998
    Date of Patent: May 1, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Christina Y. Chan, Jerald C. Sadoff
  • Patent number: 6214354
    Abstract: Herpes Zoster, or varicella related post herpetic neuralgia is alleviated by immunizing people at risk of developing herpes zoster with varicella zoster virus (VZV) antigen.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: April 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Gary B. Calandra, Philip J. Provost, Myron J. Levin, C. Jo White
  • Patent number: 6210683
    Abstract: Compositions are provided for improving the stability of live virus vaccines containing, e.g., live varicella zoster, measles, mumps, and rubella viruses. Such improved stabilizers are aqueous solutions containing recombinant human serum albumin (rHA) as a component at from 1-100 g/l. Live virus vaccines as well as methods of preparing live virus vaccines containing the stabilizers are also provided.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: April 3, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Carl Burke, David Volkin
  • Patent number: 6110701
    Abstract: A complementary DNA (cDNA) encoding full length form of ICE.sub.rel -II is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE.sub.rel -II. The cDNA and the recombinant ICE.sub.rel -II protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE.sub.rel -II protein may be used to identify compounds that affect ICE.sub.rel -II function, inflammation and cell apoptosis. ICE.sub.rel -II function, inflammation and cell apoptosis may also be modulated by ICE.sub.rel -II antisense or gene therapy.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: August 29, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Donald W. Nicholson, Ambereen Ali, Neil A. Munday, John P. Vaillancourt
  • Patent number: 6107087
    Abstract: The invention discloses a cDNA consisting of human cyclooxygenase-2 cDNA attached to 3'flanking sequence of human cyclooxygenase-1 methods for increasing the expression of human cyclooxygenase-2 in transformed cell and assays for preferentially and independently measuring cyclogense-2 in samples.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: August 22, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Gary P. O'Neill, Joseph A. Mancini
  • Patent number: 6103513
    Abstract: A complementary DNA (cDNA) encoding full length form of ICE.sub.rel -II is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE.sub.rel -II. The cDNA and the recombinant ICE.sub.rel -II protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE.sub.rel -II protein may be used to identify compounds that affect ICE.sub.rel -II function, inflammation and cell apoptosis. ICE.sub.rel -II function, inflammation and cell apoptosis may also be modulated by ICE.sub.rel -II antisense or gene therapy.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: August 15, 2000
    Assignee: Merck Frosst Canada & Co.
    Inventors: Donald W. Nicholson, Ambereen Ali, Neil A. Munday, John P. Vaillancourt
  • Patent number: 6090623
    Abstract: Isolated DNA encoding each of human calcium channel .alpha..sub.1 -, .alpha..sub.2 -, .beta.- and .gamma.-subunits, including subunits that arise as splice variants of primary transcripts, is provided. In particular DNA clones encoding each of the .alpha..sub.1A-1, .alpha..sub.1A-2, .alpha..sub.1E-1, .alpha..sub.1C-2, .alpha..sub.1E-3, .beta..sub.3-1, .beta..sub.2C, .beta..sub.2D, .beta..sub.2E and .beta..sub.4 subunits of human calcium channels are provided. Cells and vectors containing the DNA, subunit specific antibodies and nucleic acid probes and methods for identifying compounds that modulate the activity of human calcium channels are also provided.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: July 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Michael M. Harpold, Steven B. Ellis, Mark E. Williams, Ann F. McCue
  • Patent number: 6051238
    Abstract: Vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability are disclosed. The vaccine formulations comprise an increased amount of a 6-carbon polyhydric alcohol (such as sorbitol), an increase amount of a disaccharide (such as sucrose) and an amount of a physiologically active buffer to adjust the pH from about 6.0 to about 7.0.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Carl J. Burke, Su-Pi Sheu
  • Patent number: 5997880
    Abstract: Herpes Zoster, or varicella related post herpetic neuralgia is alleviated by immunizing people at risk of developing herpes zoster with varicella zoster virus (VZV) antigen.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: December 7, 1999
    Assignees: Merck & Co., Inc., University of Colorado
    Inventors: Gary B. Calandra, Philip J. Provost, Myron J. Levin, C. Jo White
  • Patent number: 5955337
    Abstract: The DNA encoding glucan synthesis gene 1 (GLS1) is cloned and used in an in vitro assay to screen for compounds that modulate 1,3 .beta.-D glucan synthase activity.
    Type: Grant
    Filed: November 21, 1996
    Date of Patent: September 21, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mohammed El-Sherbeini, Joseph A. Clemas
  • Patent number: 5939322
    Abstract: Through the use of the novel receptor NER in a screening procedure, TOFA (5-tetradecyloxy)-2-furan-carboxylic acid) has been found to modulate other receptors and to be a potent potentiator of other drugs. TOFA activates the NER receptor. The NER receptor is a novel member of the steroid hormone receptor family and has been prepared by cDNA cloning from a human osteosarcoma SAOS-2/B10 cell library. Also disclosed is the complete sequence of human NER cDNA; a COS stable expression system; the expressed NER protein; and an assay using the COS expression system. In addition, the invention relates to a method for identifying functional ligands of the NER receptor.
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: August 17, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Gideon A. Rodan, Su Jane Rutledge, Azriel Schmidt, Robert L. Vogel
  • Patent number: 5847112
    Abstract: Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1.0 and 1.4, intrinsic viscosities between 0.6 and 3.0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: December 8, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Peter J. Kniskern, William J. Miller, Arpi Hagopian, Charlotte C. Ip, John P. Hennessey, Jr., Dennis J. Kubek, Pamela D. Burke
  • Patent number: 5834228
    Abstract: The apopain:Ac-DEVD-CHO complex has been crystallized and its structure determined by x-ray crystallography. Based upon this crystal structure of the complex, a method for identifying inhibitors of apopain is presented which comprises designing putative inhibitors having specific contacts with apopain, making the putative inhibitors, and testing the putative inhibitors for their ability to inhibit apopain.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 10, 1998
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: Joseph W. Becker, Donald W. Nicholson, Jennifer Rotonda, Nancy A. Thornberry, Kimberly M. Fazil, Michel Gallant, Yves Gareau, Marc Labelle, Erin P. Peterson, Dita M. Rasper, Rejean Ruel, John P. Vaillancourt
  • Patent number: 5824837
    Abstract: A transgenic mouse has been prepared that expresses a human interluekin-1.beta. transgene. Expression of the transgene is mediated by a mouse metallothionein promoter. As a result of the expression of this transgene, the mouse has inflammation of its kidney and liver. The claimed animals are useful as screening tools for agents that are potentially useful for treating inflammation.
    Type: Grant
    Filed: April 22, 1996
    Date of Patent: October 20, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Howard Y. Chen, Kathryn J. Hofmann, Leonardus H. T. Van Der Ploeg, Alan R. Shaw, Myrna E. Trumbauer, Hui Zheng
  • Patent number: 5821353
    Abstract: DNA molecules encoding proteins involved in biosynthesis of 1,3-beta-D glucan are identified, cloned, expressed and used in in vitro assays to screen for antifungal compounds, including compounds that affect cell wall biosynthesis. The invention includes but is not limited to the purified DNA molecules, assays employing the DNA molecules, proteins encoded by the DNA molecules, cells expressing the DNA molecules and altered forms of the molecules.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: October 13, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Cameron M. Douglas, Gary L. Chrebet, Joseph Clemas, Mohammed El-Sherbeini, Forrest Foor, Jennifer Nielsen Kahn, Rosemarie Kelly, Jean A. Marrinan, Nancy R. Morin, Janet C. Onishi, Stephen Authur Parent, Naasa M. Ramadan, Elizabeth A. Register, Gan-Ju Shei